Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
JTE-013 HCl is a novelm potent, selective antagonist of sphingosine-1-phosphate 2 (S1P2) receptor, with IC50 of 17 and 22 nM, respectively, (IC50 >10 µM for for binding to human S1P1 and S1P3).
ln Vitro |
JTE-013 lowers cell viability at 50-200 μM for 1-3 days[1].
JTE-013 prevents S1P-induced ERK activation and reverses S1P-induced Akt inhibition[1]. JTE-013 exhibits a 4.2% inhibition of S1P3 and, at concentrations up to 10 μM, does not agitate S1P1[1]. |
---|---|
ln Vivo |
JTE-013 (gavage; 30 mg/kg daily for 14 days in a row) decreases tumor weight and size[1].
|
Cell Assay |
Cell Line: SK-N-AS cells
Concentration: 50, 100, 150, 200 μM
Incubation Time: 1-3 days
Result: Reduced cell viability.
|
Animal Protocol |
Six-week-old female athymic NCr-nu/nu nude mice
30 mg/kg Gavage; daily for 14 consecutive days |
References |
Molecular Formula |
C17H19CL2N7O
|
---|---|
Molecular Weight |
408.2851
|
Exact Mass |
407.1
|
Elemental Analysis |
C, 50.01; H, 4.69; Cl, 17.37; N, 24.01; O, 3.92
|
CAS # |
383150-41-2
|
Appearance |
Solid powder
|
SMILES |
ClC1C([H])=C(C([H])=C(N=1)Cl)N([H])C(N([H])N([H])C1C([H])=C(C2C(C([H])([H])[H])=NN(C([H])([H])[H])C=2N=1)C([H])(C([H])([H])[H])C([H])([H])[H])=O
|
Synonyms |
JTE 013; JTE-013; JTE013
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~244.92 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.83 mg/mL (2.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.83 mg/mL (2.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.4492 mL | 12.2462 mL | 24.4924 mL | |
5 mM | 0.4898 mL | 2.4492 mL | 4.8985 mL | |
10 mM | 0.2449 mL | 1.2246 mL | 2.4492 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
The biologic characteristics of JTE-013 and AB1. J Pharmacol Exp Ther . 2015 Sep;354(3):261-8. td> |
Effect of JTE-013 and AB1 on GB cell migration. J Pharmacol Exp Ther . 2015 Sep;354(3):261-8. td> |
Effect of JTE-013 and AB1 on the S1P2 signaling pathway in SK-N-AS cells. J Pharmacol Exp Ther . 2015 Sep;354(3):261-8. td> |